Antibody Drug Conjugates Market Size, Share & Industry Analysis, By Product/Target Family (HER2-directed ADCs, Nectin-4-directed ADCs, TROP2-directed ADCs, CD30-directed ADCs, and Others), By Payload Class (Topoisomerase I Inhibitor ADCs, Microtubule Inhibitor ADCs, and Others), By Disease Indication (Breast Cancer, Urothelial Cancer, Lymphoma, Lung Cancer, Ovarian Cancer, and Others), By Route of Administration (Intravenous and Others), By End User (Hospitals, Cancer Specialty Centers, Academic & Research Hospitals, Ambulatory Infusion Centers, and Others), and Regional Forecast, 2026-2034

Last Updated: May 18, 2026 | Format: PDF | Report ID: FBI116146

To get information on various segments, share your queries with us

ATTRIBUTE	DETAILS
Study Period	2021-2034
Base Year	2025
Estimated Year	2026
Forecast Period	2026-2034
Historical Period	2021-2024
Growth Rate	CAGR of 14.76% from 2026 to 2034
Unit	Value (USD Billion)
Segmentation	By Product/Target Family, Payload Class, Disease Indication, Route of Administration, End User, and Region
By Product/Target Family	HER2-directed ADCs Nectin-4-directed ADCs TROP2-directed ADCs CD30-directed ADCs CD79b-directed ADCs Folate Receptor Alpha-directed ADCs Others
By Payload Class	Topoisomerase I Inhibitor ADCs Microtubule Inhibitor ADCs Maytansinoid ADCs DNA-damaging ADCs Others
By Disease Indication	Breast Cancer Urothelial Cancer Lymphoma Lung Cancer Ovarian Cancer Gastric & Gastroesophageal Cancer Others
By Route of Administration	Intravenous Others
By End User	Hospitals Cancer Specialty Centers Academic & Research Hospitals Ambulatory Infusion Centers Others
By Region	North America (By Product/Target Family, Payload Class, Disease Indication, Route of Administration, End User, and Country) U.S. Canada Europe (By Product/Target Family, Payload Class, Disease Indication, Route of Administration, End User, and Country/Sub-region) Germany U.K. France Spain Italy Scandinavia Rest of Europe Asia Pacific (By Product/Target Family, Payload Class, Disease Indication, Route of Administration, End User, and Country/Sub-region) China Japan India Australia Southeast Asia Rest of Asia Pacific Latin America (By Product/Target Family, Payload Class, Disease Indication, Route of Administration, End User, and Country/Sub-region) Brazil Mexico Rest of Latin America Middle East & Africa (By Product/Target Family, Payload Class, Disease Indication, Route of Administration, End User, and Country/Sub-region) GCC South Africa Rest of Middle East & Africa